Y. Zhai

发表

Identification and Characterization of a Novel Cytokine, THANK, aTNF Homologue That ActivatesApoptosis, Nuclear Factor-κB, and c-Jun NH2-Terminal Kinase*

B. Aggarwal, A. Mukhopadhyay, Jian Ni, 1999, The Journal of Biological Chemistry.

LIGHT, a TNF-Like Molecule, Costimulates T Cell Proliferation and Is Required for Dendritic Cell-Mediated Allogeneic T Cell Response1

Lieping Chen, S. Nagata, Y. Zhai, 2000, The Journal of Immunology.

Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.

S. Rosenberg, Y. Zhai, P. Spiess, 1996, Journal of immunology.

Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen.

S. Rosenberg, Y. Zhai, V. Bronte, 1996, Journal of immunology.

Overcoming acquired resistance to third-generation EGFR inhibitors by targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition, Bax activation, or both

T. Owonikoko, S. Ramalingam, Shi-Yong Sun, 2022, Oncogene.

Response Dendritic Cell-Mediated Allogeneic T Cell T Cell Proliferation and Is Required for LIGHT , a TNF-Like Molecule , Costimulates

Lieping Chen, S. Nagata, Y. Zhai, 2000 .

Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100.

S. Rosenberg, M. Nishimura, Y. Zhai, 1997, Journal of immunotherapy.

Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models

Shaomeng Wang, Dajun Yang, Jianyong Chen, 2022, BMC cancer.

Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia

Y. Zhai, Jian Huang, Jiajia Pan, 2022, Journal of translational medicine.

Inhibition of angiogenesis and breast cancer xenograft tumor growth by vegi, a novel cytokine of the tnf superfamily

Zheng Wang, J. Lu, Y. Zhai, 1999, International journal of cancer.

Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

Dajun Yang, Ya-Zhen Qin, Q. Jiang, 2022, Journal of Hematology & Oncology.

immunization with a recombinant adenovirus Therapeutic antitumor response after

S. Rosenberg, Y. Zhai, V. Bronte, 2001 .

Burden of tyrosine kinase inhibitor failure in Chinese chronic myeloid leukemia patients: a systematic literature review.

Dajun Yang, Y. Zhai, Wendong Chen, 2022, Journal of comparative effectiveness research.

Therapeutic potential of the novel Bcl‐2/Bcl‐XL dual inhibitor, APG1252, alone or in combination against non‐small cell lung cancer

Shi-Yong Sun, Y. Zhai, Dongsheng Wang, 2022, Molecular carcinogenesis.

Light stimulates IFNgamma-mediated intercellular adhesion molecule-1 upregulation of cancer cells.

Xin-Yuan Fu, Dajun Yang, Y. Zhai, 2003, Human immunology.

A phase I study of novel dual Bcl-2/Bcl-xL inhibitor APG-1252 in patients with advanced small cell lung cancer (SCLC) or other solid tumor.

A. Tolcher, K. Papadopoulos, D. Rasco, 2018 .

338 BM-1252 (APG-1252): a potent dual specific Bcl-2/Bcl-xL inhibitor that achieves complete tumor regression with minimal platelet toxicity

Liu Liu, Shaomeng Wang, Chao-yie Yang, 2014 .

A Phase I Study of Novel Bcl‐2/Bcl‐xL Inhibitor APG‐1252 in Patients with Advanced SCLC or Other Solid Tumor: OA12

D. Rasco, Y. Wu, Dajun Yang, 2018, Journal of Thoracic Oncology.

Discovery of 4-((3′R,4′S,5′R)-6″-Chloro-4′-(3-chloro-2-fluorophenyl)-1′-ethyl-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development

Liu Liu, Shaomeng Wang, Dajun Yang, 2017, Journal of medicinal chemistry.

LIGHT, a new member of the TNF superfamily.

Y. Zhai, D. Yang, M. Zhang, 2002, Journal of biological regulators and homeostatic agents.

Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.

F. Marincola, S. Rosenberg, P. Hwu, 1998, Journal of the National Cancer Institute.

MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment

Dajun Yang, Y. Zhai, P. Zou, 2019, Journal of Immunotherapy for Cancer.

LIGHT sensitizes IFNgamma-mediated apoptosis of MDA-MB-231 breast cancer cells leading to down-regulation of anti-apoptosis Bcl-2 family members.

Dajun Yang, Y. Zhai, Manchao Zhang, 2003, Cancer letters.

LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer.

B. Kwon, J. Lu, R. Gentz, 1998, The Journal of clinical investigation.

A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma

H. Yi, Jing Wang, Y. Zhai, 2018, Journal of experimental & clinical cancer research : CR.

A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors.

D. Rasco, Dajun Yang, Y. Zhai, 2019, Journal of Clinical Oncology.

FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia

Dajun Yang, Y. Zhai, Hengrui Zhu, 2021, Translational oncology.

Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors

Dajun Yang, Y. Zhai, M. Qiu, 2019, Cell & Bioscience.

A Newly Identified Member of Tumor Necrosis Factor Receptor Superfamily (TR6) Suppresses LIGHT-mediated Apoptosis*

Jian Ni, Y. Zhai, B. Kwon, 1999, The Journal of Biological Chemistry.

TRANK, a novel cytokine that activates NF-kappa B and c-Jun N-terminal kinase.

B. Aggarwal, Y. Zhai, L. V. Van Eldik, 1998, Journal of immunology.

Cutting Edge: TRANK, a Novel Cytokine That Activates NF-κB and c-Jun N-Terminal Kinase

B. Aggarwal, Y. Zhai, Guo-liang Yu, 1998, The Journal of Immunology.

VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo

B. Aggarwal, R. Gentz, S. Ruben, 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models

Dajun Yang, Y. Zhai, Yan Yin, 2021, Cell death discovery.

Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials

Dajun Yang, Q. Jiang, Y. Zhai, 2020 .

Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

Dajun Yang, Q. Jiang, Y. Zhai, 2022, Journal of Hematology & Oncology.

A Five-Year Follow-up on Safety and Efficacy of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) in China

Dajun Yang, Q. Jiang, Xiao-jun Huang, 2022, Blood.

Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

E. Jabbour, Dajun Yang, Y. Zhai, 2022, Blood.

An Updated Safety and Efficacy Results of Phase 1 Study of HQP1351, a Novel 3rd Generation of BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI Resistant Chronic Myeloid Leukemia

Dajun Yang, Q. Jiang, Xiao-jun Huang, 2019, Blood.

BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytoma.

David C. Jones, S. Pfister, A. von Deimling, 2022, Neuro-oncology.

A phase I study of a novel MDM2-P53 antagonist APG-115 in Chinese patients with advanced soft tissue sarcomas.

Dajun Yang, Y. Zhai, Li Zhang, 2019, Journal of Clinical Oncology.

Abstract 2058: BCL-2 selective inhibitor APG-2575 synergizes with BTK inhibitor in preclinical xenograft models of follicular lymphoma and diffuse large B-cell lymphoma

Dajun Yang, Shoulai Gu, Y. Zhai, 2019, Experimental and Molecular Therapeutics.

A phase Ib/II study of APG-115 in combination with pembrolizumab in patients with unresectable or metastatic melanomas or advanced solid tumors.

A. Tolcher, Y. Zhai, Y. Huang, 2019 .

Promising antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor- (TKI-) resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST).

Dajun Yang, K. Tao, Y. Zhai, 2022, Journal of Clinical Oncology.

Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors

Dajun Yang, Y. Zhai, M. Qiu, 2019, Cell & Bioscience.

First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs).

M. Konopleva, A. Chanan-Khan, Dajun Yang, 2021 .

544 Preclinical studies of a dual Bcl-2/Bcl-xL inhibitor APG-1252 with strong anti-tumor efficacy and significantly reduced platelet toxicity

Shaomeng Wang, Dajun Yang, D. McEachern, 2014 .

Antitumor Activity of Dual BCL-2/BCL-Xl Inhibitor Pelcitoclax (APG-1252) in Natural Killer/T-Cell Lymphoma (NK/TCL)

Dajun Yang, Y. Zhai, L. Rui, 2021, Blood.

Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

Dajun Yang, Y. Zhai, Yongping Song, 2022, Journal of Hematology & Oncology.

Potential drug-drug interaction of olverembatinib (HQP1351) using physiologically based pharmacokinetic models

Yangyu Zhao, Y. Zhai, Dongyang Liu, 2022, Frontiers in Pharmacology.

Update of Olverembatinib (HQP1351) Overcoming Ponatinib and/or Asciminib Resistance in Patients (Pts) with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph + ALL)

H. Kantarjian, E. Jabbour, Dajun Yang, 2023, Blood.

Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study

Dajun Yang, Y. Zhai, Q. Niu, 2023, Blood.

A phase 2 study of alrizomadlin (APG-115) in combination with pembrolizumab in patients with unresectable or metastatic cutaneous melanoma that has failed immuno-oncologic (IO) drugs.

J. Reeves, A. Tolcher, Dajun Yang, 2023, Journal of Clinical Oncology.

MDM2-p53 Inhibitor Alrizomadlin (APG-115) Enhances Antitumor Activity of Pomalidomide in Multiple Myeloma (MM)

Dajun Yang, Y. Zhai, P. Min, 2022, Blood.

Trial in Progress: Phase 1b/2 Study of Alrizomadlin (APG-115), Alone or Combined with 5-Azacitidine (AZA), in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), or Myelodysplastic Syndrome (MDS)

T. Kadia, Dajun Yang, Y. Zhai, 2022, Blood.

Phase I/II study of a novel MDM-2 inhibitor (APG-115) in TP53 wild type salivary gland cancers

A. Pearson, Y. Zhai, E. Bellile, 2022, European Journal of Cancer.